Thomas James Curtis

Dr. Thomas James Curtis

Obstetrics & Gynaecology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, Norfolk, UK
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2025 in International Urogynecology Journal
Verified
Journal Article
Closed access
PDF file
Thomas James CurtisThomas James Curtis
Thomas James Curtis
CCCharlotte Chant
Charlotte Chant
SQStuart Quek
Stuart Quek
IGIlias Giarenis
Ilias Giarenis
TGThomas Giles Gray
Thomas Giles Gray

18 December 2023 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
Thomas James CurtisThomas James Curtis
Thomas James Curtis
SMSambit Mukhopadhyay
Sambit Mukhopadhyay
IGIlias Giarenis
Ilias Giarenis
TGThomas Giles Gray
Thomas Giles Gray

31 March 2025 in International Neurourology Journal
Verified
Journal Article
Open access
PDF file
Thomas James CurtisThomas James Curtis
Thomas James Curtis
MDMichelle Drolet
Michelle Drolet
TGThomas Giles Gray
Thomas Giles Gray
IGIlias Giarenis
Ilias Giarenis
Purpose: Cystoscopic intravesical onabotulinumtoxinA injection is a safe and effective minimally invasive treatment for refractory overactive bladder. While the procedure can be performed in outpatient clinics under local anesthetic, some clinicians still use sedation or general anesthesia in an operating theatre. Our study aimed to assess acceptability of intravesical onabotulinumtoxinA injection versus widely accepted diagnostic cystoscopy in the outpatient setting via the medium of patient experience.Methods: A 16-item patient experience survey was administered following diagnostic cystoscopy or intravesical onabotulinumtoxinA injection in an outpatient clinic. Both procedures were performed using a flexible cystoscope with local anesthetic gel. A visual analogue scale (VAS) assessed intraprocedure pain. Dichotomous questions assessed whether significant pain or postprocedure symptoms were experienced and if these required medical attention. A free-text question assessed which symptoms had occurred.Results: One hundred responses from 188 patients were received (53.2% response rate). Sixty-eight patients underwent cystoscopic intravesical onabotulinumtoxinA injection and 32 diagnostic cystoscopy. Mean VAS scores were higher for onabotulinumtoxinA injection (24 of 100) than diagnostic cystoscopy (11 of 100) (P=0.002). VAS scores were higher among patients reporting preprocedure anxiety (31 of 100 vs. 14 of 100, P=0.0013). Twenty-four percent of onabotulinumtoxinA injection patients experienced symptoms postprocedure versus 41% for cystoscopy. Medical attention was sought more frequently in the diagnostic cystoscopy group (9.4% vs. 1.5%). Common symptoms following both procedures were dysuria, urinary frequency, urgency, abdominal pain and urine discoloration.Conclusions: Cystoscopic intravesical injection of onabotulinumtoxinA appears more painful than diagnostic cystoscopy. However, as VAS scores were relatively low, this is unlikely to represent clinically significant discomfort burdensome to the patient. There were no significant complications postprocedure. Cystoscopic intravesical onabotulinumtoxinA injection is acceptable in an outpatient setting.

13 September 2025 in International Urogynecology Journal
Verified
Journal Article
Closed access
PDF file
Thomas James CurtisThomas James Curtis
Thomas James Curtis
JSJenna Sweeney
Jenna Sweeney
TGThomas Giles Gray
Thomas Giles Gray


9 September 2026 in International Urogynecology Journal
Verified
Journal Article
Closed access
PDF file
Thomas James CurtisThomas James Curtis
Thomas James Curtis
YMYashna Mirchandani
Yashna Mirchandani
GSGrace Stott
Grace Stott
CCCharlotte Chant
Charlotte Chant
TGThomas Giles Gray
Thomas Giles Gray